Background: In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …

Ongoing emergence of SARS-CoV-2 Omicron subvariants and their rapid worldwide spread
pose a threat to public health. From November 2022 to February 2023, newly emerged …

Background Nirmatrelvir/ritonavir, the first severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) protease inhibitor, reduces the risk of hospitalization and death by …

Background Simnotrelvir is an oral 3-chymotrypsin–like protease inhibitor that has been
found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 …

Background The effects of nirmatrelvir/ritonavir (NMV/r [Paxlovid]) on coronavirus disease
2019 (COVID-19) outcomes in younger vaccinated adults are unclear. The objective of this …

Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there have
been multiple peaks of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus …

Genetically distinct viral variants of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have been recorded since January 2020. Over this time global vaccine programs …

Background Viral rebound after nirmatrelvir–ritonavir treatment has implications for the
clinical management and isolation of patients with COVID-19. We evaluated an unselected …

To the Editor, Nirmatrelvir/ritonavir (Paxlovid) is an oral antiviral drug that has been shown to
reduce the risk of hospitalization, severe COVID‐19, and mortality among mild‐to‐moderate …

In vitro data suggest the monoclonal antibody sotrovimab may have lost inhibitory capability
against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron …